SRT 1460 is a potent Sirtuin-1 (SIRT1) activator with an EC1.5 value of 2.9 μM.
Description :
SRT 1460 (2-6μM; 72 hours) inhibits cell viability in a dose-dependent manner, with all pancreatic cancer cells being more sensitive than the control HPDE cell. The IC50s of those cells are: Patu8988t, 1.62±0.13 μM; SU86.86, 2.31±0.23 μM; Panc-1, 0.66 ±0.02 μM; HPDE, 2.39±0.29 μM[2]. SRT 1460 (5μM; 16 hours) increases expression of the autophagy marker LC3-II[2].
SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol; improves insulin sensitivity, lowers plasma glucose, and increases mitochondrial capacity in obese mice model.